Compare Iron Mountain Inc (IRM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Organon & Co. Common Stock — how do they compare? Iron Mountain Inc trades at $111.23 (market cap $34.12B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Iron Mountain Inc is far larger — about 9.4× Organon & Co. Common Stock's market cap, and Iron Mountain Inc pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Organon & Co. Common Stock for 0 Days on average.
| IRM | OGN | |
|---|---|---|
Market Cap | $34.12B | $3.62B |
Volume | 1,143,756 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $13.81 |
52-Week Low | $78.86 | $5.70 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.53B | $11.04B |
Dividend Yield | 3.02% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $110.86, down 3.68% on the day, amid a neutral technical signal. The company shows steady revenue growth, with 2025 revenue at $6.90B and a net income margin of 5.54%, though profitability has been volatile. Recent news highlights expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus is bullish with a $142.75 price target, but high debt levels and negative shareholder equity pose fundamental concerns.
The outlook for IRM is mixed; growth in digital and data center services offers upside, supported by strong analyst buy ratings. However, elevated valuation multiples, significant debt burden, and inconsistent earnings present risks. Investors should weigh the growth potential against financial leverage and margin pressures when considering a position.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
